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ABSTRACT
The concept of antibody mediated CNS disorders is
relatively recent. The classical CNS paraneoplastic
neurological syndromes are thought to be T cell
mediated, and the onconeural antibodies merely
biomarkers for the presence of the tumour. Thus it was
thought that antibodies rarely, if ever, cause CNS
disease. Over the past 10 years, identiﬁcation of
autoimmune forms of encephalitis with antibodies
against neuronal surface antigens, particularly the
voltage gated potassium channel complex proteins or the
glutamate N-methyl-D-aspartate receptor, have shown
that CNS disorders, often without associated
tumours, can be antibody mediated and beneﬁt from
immunomodulatory therapies. The clinical spectrum
of these diseases is not yet fully explored, there may be
others yet to be discovered and some types of more
common disorders (eg, epilepsy or psychosis) may prove
to have an autoimmune basis. Here, the known
conditions associated with neuronal surface antibodies
are brieﬂy reviewed, some general aspects of these
syndromes are considered and guidelines that could help
in the recognition of further disorders are suggested.
INTRODUCTION
Well recognised conditions such as myasthenia
gravis (MG) and the LamberteEaton myasthenic
syndrome (LEMS) have been shown by rigorous
experimental approaches to be antibody mediated.
The antibodies are directed against essential
membrane receptors or ion channels involved in
transmission at the neuromuscular junction; the
antibodies bind to extracellular epitopes on the
membrane proteins; plasma exchange leads to clear
clinical beneﬁt; and both in vitro and passive
transfer experiments show that the IgG antibodies
are pathogenic.
1
Several antibodies to ‘onconeural’ antigens are
found in CNS disorders associated with cancers
(paraneoplastic neurological syndromes),
2e4
including antibodies to Hu (Hu-Abs), and many
others.
5 However, as the targets of these antibodies
are intracellular proteins, and patients do not
usually improve with immunotherapy, their path-
ogenic roles are not clear. Rather, it is thought
that Tcell cytotoxicity is a more likely mechanism
to account for the neuronal cell loss that occurs
in these rare but serious conditions. T cell cyto-
toxicity could also contribute in patients with
antibodies to glutamic acid decarboxylase (GAD-
Abs) as these are also directed against an intracel-
lular antigen, but at very high levels are associated
with non-paraneoplastic forms of stiff person
syndrome (SPS) and other CNS disorders.
67
Over the past few years it has become increas-
ingly clear that there are CNS syndromes associated
with antibodies that bind to cell surface determi-
nants of membrane associated proteins on neuronal
cells and are likely to be pathogenic.
8 9 Here we call
these antibodies ‘neuronal surface antibodies’
(NSAbs), and the diseases associated with them,
NSAb syndromes (NSAS). These syndromes can be
indistinguishable at presentation from classical
paraneoplastic syndromes, such as limbic encepha-
litis (LE), but one is a newly deﬁned entity,
N-methyl-D-aspartate receptor antibody (NMDAR-
Ab) encephalitis.
10 These syndromes can be diag-
nosed by serum/CSF antibody tests, are not so rare,
are frequently non-paraneoplastic and they respond
to immunotherapy with a good chance of
substantial recovery.
8e12
Although these syndromes are beginning to be
widely recognised, there are likely to be others for
which no NSAb has yet been deﬁned and in which
immunotherapies have not yet been tested. There is
a need, therefore, to deﬁne guidelines for their
recognition so that an immune mediated basis can
be explored. In this review, we start by comparing
conditions that are associated with antibodies to
intracellular antigens with those that are associated
with antibodies to cell surface antigens. We then
summarise the main clinical and paraclinical
features of the syndromes that have already been
identiﬁed and, largely from these observations,
suggest guidelines for recognising these and other
immune mediated conditions in the future. We
concentrate on the diseases predominantly
affecting the ‘grey’ matter, and will not include
those diseases such as neuromyelitis optica and
acute disseminated encephalomyelitis in which
antibodies to‘white’ matter glial or myelin antigens
have also recently been discovered.
13 14
GENERAL FEATURES OF DISEASES ASSOCIATED
WITH ANTIBODIES TO INTRACELLULAR
ANTIGENS VERSUS THOSE WITH NSABS
Table 1 summarises some features of the CNS
autoimmune syndromes according to the presence
of onconeural antibodies or NSAbs. Patients with
onconeural Abs present at ages which are typical of
the tumours but those with NSAbs can occur at
any age. LE and the more complex NMDAR-Ab
encephalopathy are, to date, the most frequent
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Neuro-immunologypresentations in the NSAS and more common than either
cerebellar degeneration or encephalomyelitis with onconeural/
intracellular antibodies. Tumours can be present, particularly
small cell lung cancer (SCLC), ovarian and breast cancers with
onconeural antibodies, and ovarian teratomas, thymomas, breast
and lung cancers with the NSAS, but many of the NSAS
patients do not have tumours. Evidence of CSF inﬂammation,
including oligoclonal bands, can be present in both groups but
a normal CSF is more common with some of the NSAS.
2 389
The most important distinctions relate to the course and
treatment responses. Patients with onconeural antibodies
usually present subacutely and often have a relentlessly
progressive course, despite immunotherapies, although there
may be stabilisation of the neurological syndrome if tumour
treatment is effective.
4 By contrast, patients with NSAbs may
have an acute or subacute onset, usually with short duration to
nadir, and can make a very good response to immunotherapies.
In additions to tumour treatment if required; in many cases
immunotherapies can be weaned over a year or two, suggesting
that the condition is monophasic.
8
It is generally accepted that the onconeural antibodies are
markers for the immune mediated process but not pathogenic;
Tcell cytotoxicity towards the same or other antigens is thought
to be causative, mostly based on postmortem observations of
abundant T cell inﬁltrates in the brain parenchyma in close
apposition with neurons. The NSAS are not well studied yet
but T cell inﬁltration is less conspicuous in the few reports of
patients with anti-NMDAR encephalitis.
4 68
WELL DEFINED CNS SYNDROMES ASSOCIATED WITH NSABS
Features of the main syndromes recognised so far are summar-
ised in table 2. NSAbs have, of course, been described in the
neuromuscular junction disorders, as mentioned above. In CNS
syndromes, voltage gated potassium channel (VGKC)-Abs were
ﬁrst identiﬁed by immunoprecipitation in Morvan’s syndromes
and then in non-paraneoplastic LE.
15 16 Voltage gated calcium
channels (VGCC) and metabotropic glutamate receptor 1
(mGluR1) antibodies were found in some patients with cere-
bellar degeneration (see below).
17 18 In LE, serum VGKC-Abs
were also shown to label rodent hippocampus by indirect
immunohistochemistry,
16 and these and other serum or CSF
antibodies that bind to the hippocampal molecular layer region
rich in synaptic connections were subsequently designated
‘neuropil’ antibodies.
19 A novel and frequent target is the NMDA
sensitive glutamate receptor,
20 while other less frequent neuropil
antibodies are against a-amino-3-hydroxy-5-methyl-4-isoxazo-
lepropionic acid (AMPA),
21 gamma-aminobutyric acid B
(GABAB)
22 and type 5 metabotropic glutamate (mGluR5)
receptors.
23 Subsequently, it became clear that antibodies
immunoprecipitating VGKC extracted from mammalian brain
do not target the VGKC, as originally thought,
16 24 25 but
proteins that are tightly complexed with VGKC in situ, mainly
leucine rich glioma inactivated 1 protein (LGI1) or contactin
associated protein 2 (CASPR2).
26e28 Both of these proteins are
expressed in the hippocampus although the localisation is subtly
different.
26 We now call these antibodies VGKC complex anti-
bodies generically, or LGI1 and CASPR2 speciﬁcally. Contactin
2 is another component of the complex but antibodies to this
protein are not very common.
26
Limbic encephalitis
LE is a well recognised condition characterised by subacute
development of short term memory loss, behavioural change
and seizures involving the temporomedial lobes and the
Table 1 CNS syndromes associated with antineuronal antibodies
Classical paraneoplastic CNS syndromes
associated with onconeural antibodies
CNS syndromes associated with neuronal
surface antibodies
Main syndromes PCD
Encephalomyelitis
LE
Brainstem encephalitis
LE
Morvan’s syndrome
NMDAR-Ab encephalitis
PERM
Cerebellar ataxia
Age range (years) and sex Mainly adults (40e70); both genders
(PCD more frequent in women).
NMDAR-Ab encephalitis common in children
and young women
Antibodies commonly detected or
recently reported
Antibodies against intracellular antigens
or PNS related onconeural antibodies
(Hu, Yo, Ri, Ma2, Cv2/CRMP5, amphiphysin, Sox1/2)
Antibodies to VGKC complex antigens
(LGI1 or CASPR2), NMDAR, AMPAR,
GABABR, GlyR, VGCC-Ab, mGluR1, mGluR5*
Tumours SCLC, breast, ovary, testicular Teratoma, thymoma, SCLC, breast
No tumour found in many cases, particularly
LE associated with LGI1-Ab
Relationship between antibody
and tumour
Antibody usually indicates the presence
of a particular tumour type
Antibody presence does not indicate
if a case is paraneoplastic
Immunotherapy Not usually effective Generally effective
Outcome Poor; improvement or stabilisation related
mainly to tumour treatment
Variable but generally good; possible
spontaneous remission
Neuropathology Loss of neurons, gliosis, T cell inﬁltrates in
close apposition to neurons, some with
immunophenotype of cytotoxic T cells
Limited data Variable T cells,
B cells and plasma cell inﬁltrates but less
intense than in patients with paraneoplastic
disease.
9a
Prevalent pathogenic mechanism Antibodies are markers for the tumour and
are not likely to be pathogenic. T cell
cytotoxicity is the proposed pathogenic
mechanism
Autoantibody mediated, probably downregulation
of target antigen but may be complement
mediated damage in some conditions
*Glutamic acid decarboxylase (GAD) antibodies are not neuronal surface antibodies as they target an intracellular antigen but they do not generally associate with tumours, and are
considered to be markers of immune mediated syndromes.
AMPAR, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2, contactin associated protein 2; GABABR, gamma-aminobutyric acid B receptor; GlyR, glycine receptor;
LE, limbic encephalitis; LGI1-Ab, leucine rich glioma inactivated 1 protein antibody; mGluR, metabotropic glutamate receptor; NMDAR-Ab, N-methyl-D-aspartate receptor antibody; PCD,
paraneoplastic cerebellar degeneration; PERM, progressive encephalomyelitis with rigidity and myoclonus; PNS, paraneoplastic neurological syndromes; SCLC, small cell lung cancer; VGCC-
Ab, voltage gated calcium channel antibody; VGKC, voltage gated potassium channel.
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Neuro-immunologyamygdalae, with variable evidence of CSF inﬂammation and
neuronal antibodies.
2 29 For years it was considered a rare
paraneoplastic disorder with a poor prognosis but it is now
recognised that LE is frequently non-paraneoplastic.
93 0In a few
cases reported, a single clinical feature (eg, seizures, amnesia,
delirium, psychosis) can be prominent or isolated; therefore, the
concepts of autoimmune forms of encephalopathy, psychiatric
disorders, epilepsy or dementia are beginning to be explored (for
example, see Vincent et al,
31 Flanagan et al,
32 Vernino et al,
33
Zandi et al
34and Kayser et al
35).
LE associated with VGKC complex antibodies
VGKC-Abs associated LE was the ﬁrst immunotherapy respon-
sive NSAb associated CNS syndrome to be well characterised
30 36
and since then it has become widely recognised. A high
proportion of patients with LE have LGI1-Abs, and a few have
CASPR2-Abs, but there are other VGKC complex proteins yet to
be deﬁned and the antibodies are best identiﬁed by the estab-
lished radioimmunoprecipitation assay.
24 26 Approximately 60%
of patients have MRI evidence of medial temporal lobe inﬂam-
mation but pleocytosis or other CSF changes are uncommon,
and oligoclonal bands are rare.
26 30 Patients respond within a few
weeks to intense immunotherapies with good or very good
outcomes, but even without treatment a few patients have
shown spontaneous improvement.
16 26 Interestingly, a distinc-
tive seizure semiology, termed faciobrachial dystonic seizures,
can be identiﬁed before manifestation of LE, and these seizures
respond rapidly to immunotherapies, which might prevent the
onset of cognitive dysfunction and more widespread seizures in
future cases.
12
A rarer condition associated with VGKC-complex-Abs is
Morvan’s syndrome, characterised by insomnia and psychosis,
peripheral nerve hyperexcitability (including neuromyotonia and
pain) and dysautonomic features.
15 37 38 CASPR2-Abs are more
common than LGI1-Abs in Morvan’s syndrome but some
patients have both speciﬁcities or neither. Around 40% of
patients with Morvan’s syndrome have tumours, often recur-
rent or malignant thymomas, sometimes associated with
previous MG, and these patients have a poor prognosis.
However, those patients without tumours do well with
immunotherapies.
26
Less frequent NSAbs associated with LE
LE can also associate with antibodies against AMPA and GABAB
receptors.
21 22 These often have a classical LE phenotype and
many have tumours, including SCLC, thyroid and breast
tumours. There may be prominent psychiatric features with
AMPA receptor antibodies (AMPAR-Abs) and prominent
seizures with GABAB receptor antibodies (GABABR-Abs) but
only small cases series have been reported so far.
21 22 39 40
GABABR-Abs are probably the most common antibodies found
in LE in association with SCLC, previously thought to be
‘seronegative’ for onconeural antibodies.
40 41 Most of the
patients with GABABR-Abs or AMPAR-Abs who receive
immunotherapy and cancer treatment show neurological
improvement although relapses have been observed with
AMPAR-Abs.
21 22
Another novel NSAb has been recently described against type
5 mGluR (mGluR5) in two patients with prominent limbic
encephalopathy and Hodgkin lymphoma (namely Ophelia
syndrome).
23
Although not NSAbs, GAD-Abs have been identiﬁed in
younger females with a form of LE, presenting mainly with
temporal lobe epilepsy and MRI evidence of temporal lobe
inﬂammation; these patients did not usually respond well to
immunotherapies but were not treated aggressively at onset.
42
NMDAR-Ab encephalitis
The encephalitis associated with NMDAR-Ab is a well charac-
terised and recognisable condition, distinct from the forms of LE
Table 2 Neuronal surface antibody associated syndromes
Syndrome Antibodies Particular clinical features Possible tumours
Immunotherapy
response
In vitro evidence of Ab
pathogenicity
Frequency or No of
cases reported
NMDAR-Ab
encephalitis
NMDAR Dyskinetic movements,
decreased consciousness,
psychiatric presentation in
young women. Epilepsy and
abnormal movements more
frequent at onset in children
Ovarian teratoma. Rare
in children. Up to 50%
after age 18 years
Yes In vitro and in vivo reduction
of NMDA receptors
Common syndrome.
More than 500 cases
reported, mainly in USA
LE LGI1
CASPR2
(<10%)
Male predominance, hyponatraemia,
faciobrachial dystonic seizures,
myoclonus
Rare with LGI1-Ab.
Thymoma in some
with CASPR2-Ab
Yes In vitro production of
epileptogenic activity in
brain slices
Common syndrome
More than 600 cases
reported, mainly in UK
AMPAR Possible isolated psychiatric
symptoms
70% (lung, breast,
thymus)
Yes, frequent
relapses
Downregulation of AMPA
receptors
14
GABABR Prominent seizures 60% (SCLC) Yes None 25
mGluR5 Ophelia syndrome Hodgkin lymphoma Unknown None 2
Morvan’s
syndrome
CASPR2 Encephalopathy, peripheral
nerve hyperexcitability,
dysautonomia
Thymoma Yes Not tested 9
PERM GlyR Encephalomyelitis with
myoclonus, rigidity and
brainstem signs
Thymoma Yes Not tested 6
Cerebellar
ataxia
VGCC Possible coexistence
of LEMS
SCLC Poor Not tested 16
mGluR1 Remote history of Hodgkin
lymphoma
Hodgkin lymphoma Yes In vivo 3
The frequencies given depend on reported cases. Many cases are being diagnosed but are not reported.
Ab, antibody; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AMPAR, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2, contactin associated
protein 2; GABABR, gamma-aminobutyric acid B receptor; GlyR, glycine receptor; LE, limbic encephalitis; LEMS, Lambert-Eaton myasthenic syndrome; LGI1-Ab, leucine rich glioma
inactivated 1 protein antibody; mGluR, metabotropic glutamate receptor; NMDA, N-methyl-D-aspartate; NMDAR, N-methyl-D-aspartate receptor; PERM, progressive encephalomyelitis with
rigidity and myoclonus; SCLC, small cell lung cancer; VGCC, voltage gated calcium channel.
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Neuro-immunologydescribed above.
10 However, in distinction to most patients with
typical LE, a high proportion of patients are children or young
women who may initially be seen or admitted to psychiatric
wards for acute anxiety, behavioural change or psychosis.
Within a few days the presence of seizures or neuropsychological
deﬁcits is recognised, deﬁning an organic condition, and within
days or weeks reduced consciousness, movement disorders,
hypoventilation and autonomic imbalance often require admis-
sion to intensive care units.
10 Up to 50% of young adult female
patients have an ovarian teratoma, but these are much less
common in children.
10 11 Importantly, MRI is frequently not
informative but pleocytosis at onset is very common.
10 11 In
children, the disease can present with behavioural disturbance
and dyskinesias
43 and in the past such patients have often been
classiﬁed as encephalitis lethargica.
44 Relapses can occur in
20e25% of non-paraneoplastic patients and they can be sepa-
rated by months or years.
10 11
PERM and GlyR-Ab associated conditions
A few patients with a well recognised but rare condition,
progressive encephalomyelitis with rigidity and myoclonus
(PERM), which is part of the spectrum of SPS,
45 have GAD-Abs
but some are now being identiﬁed with antibodies against
glycine receptors (GlyR-Abs).
46e48 PERM was initially described
as a subacute disorder characterised by muscle rigidity, stimulus
sensitive spasms, brainstem dysfunction with poor prognosis
and pathological ﬁndings (often post mortem) of perivascular
lymphocyte cufﬁng and neuronal loss in the brainstem and
spinal cord. Generalised myoclonus, hyperekplexia, cerebellar
ataxia and autonomic dysfunction were later described.
45 A few
reports of GlyR-Abs in single cases and a series of three patients
show a wide spectrum of features on presentation with often
prominent brainstem dysfunction and little MRI or CSF
evidence of inﬂammation
46 47; one patient presented with an
immunotherapy responsive isolated medial temporal lobe status
epilepticus (Zuliani et al in preparation).
49 One had a thymoma,
with dramatic improvement after surgery and immuno-
therapy.
48 Despite the apparent rarity of the condition, patients
with GlyR-Abs, in distinction to most of those with GAD-Abs,
seem to do well on immunotherapies; however, one patient who
also had NMDAR-Abs died before testing for either antibody
was available.
50
Cerebellar ataxia associated with NSAbs
Antibodies (VGCC-Abs) against voltage gated calcium channels
(VGCC-Abs) were demonstrated to be present in some cases of
cerebellar degeneration in association with lung tumours.
17
However, the lack of response to immunotherapies, despite
improvement of coexistent LEMS, suggested that the antibodies
are unlikely to be contributing to the cerebellar pathology (or
alternatively that they cause permanent Purkinje cell damage
before treatment can be initiated).
17 51 Antibodies to mGluR1
were initially reported in two patients with subacute cerebellar
degeneration and a past history of Hodgkin disease and were
shown in passive transfer to lead to ataxia in experimental
animals.
18 One other patient with this antibody without
a tumour and with a partial treatment response has been
reported.
52 A recent study using a proteomic approach to iden-
tify potential NSAbs in patients with non-paraneoplastic cere-
bellar ataxia identiﬁed CASPR2-Abs in a total of nine of 88 (10%)
idiopathic ataxia patients compared with 2% in neurological
controls.
53 Systematic studies are required to examine the full
repertoire of antibodies in this heterogeneous condition early
during the disease course, and to test treatment responses.
Proof of the pathogenicity of NSAbs
Despite the very good clinical evidence that many of the
syndromes described above are antibody mediated, there is little
direct experimental evidence to prove this concept. There are
studies on the effects of the serum or CSF IgG antibodies on
neuronal function in cultured cells
21 54 55 or on brain slices
56 but
the transfer of clinical or electrophysiological evidence of disease
to experimental animals by either systemic or intrathecal
injection has not yet been reported, with the exception
of mGluR1-Ab in paraneoplastic cerebellar degeneration,
18 and
reports of GAD or amphiphysin antibodies that target intracel-
lular antigens (see below).
57 58
WELL DEFINED CNS SYNDROMES WITHOUT IDENTIFIED
NSABS
There are several syndromes which are well recognised and
generally thought to be immune mediated but in which
a potentially pathogenic antibody has not been deﬁned. Below
we remind the reader of these syndromes and recent work that
may lead to discovery of relevant NSAbs.
Stiff person syndrome and related disorders
The autoimmune basis of SPS (reviewed by Meinck and
Thompson
45) is supported by response to immunomodula-
tion,
45 59 association with organ speciﬁc autoimmune diseases,
high titre GAD-Abs (often intrathecally synthesised)
7 or
amphiphysin-Abs in paraneoplastic cases.
60 61 A direct patho-
genic role for antibodies against GAD and amphiphysin, both
intracellular antigens, is controversial but successful passive
transfer to rodents from patients both with GAD-Abs
58 and
amphiphysin-Abs
57 are encouraging, in the latter case with
evidence of internalisation of antibodies into the neurons. These
experiments suggest that there are pathogenic antibodies that
can access the presynaptic nerve terminal but more work needs
to be done to deﬁne more clearly how this occurs, and the
possibility of NSAbs coexisting with GAD-Abs needs to be
explored.
Opsoclonusemyoclonus syndrome
Opsoclonusemyoclonus syndrome (OMS) is a rare disorder
characterised by chaotic saccadic eye movements, myoclonus,
ataxia and encephalopathy. It is best characterised in infants
who often have neuroblastomas, but in some the disease appears
to be non-paraneoplastic; the acute disease remits but the chil-
dren are often left with cognitive and other problems. Immu-
notherapies appear to be of beneﬁt but no systematic studies
have been reported. There is also an idiopathic adult onset OMS,
frequently in women, who have a monophasic course with
a good response to intravenous immunoglobulins or corticoste-
roids.
62 By contrast, a paraneoplastic form of OMS is more
common in older women and associated with breast cancer and
SCLC.
63 Some evidence of possible NSAbs that are able to induce
apoptosis of neuroblastoma cell lines has been shown in children
but not in adults.
64e67
Cerebellar ataxia without identiﬁed NSAbs
Post-infectious cerebellitis
This condition is well known in children
68 but adult cases have
also been reported.
69 Like OMS, it tends to improve spontane-
ously but often leaves long term deﬁcits, especially in adults.
69
Most cases are not associated with any identiﬁed antibody
although autoantibodies cross reacting with EpsteineBarr virus
have been reported,
70 and autoimmune mechanisms are likely.
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Neuro-immunologyCerebellar ataxia associated with antibodies against non-onconeural
intracellular antigens
In cases of cerebellar ataxia without evidence of a tumour or
onconeural antibodies, there is some evidence for potential
autoimmune mechanisms. Antibodies against intracellular
antigens have been reported in patients with non-paraneoplastic
cerebellar ataxia (eg, Homer3)
71 72 and also with coexisting
coeliac disease/gluten sensitivity (ie, antigliadin antibodies cross
reacting with cerebellar antigens) although the latter hypothesis
remains controversial.
73 In addition, a more insidious course is
described in non-paraneoplastic GAD-Ab associated cerebellar
syndromes in which an autoimmune mechanism is further
supported by CSF inﬂammation and polyendocrine autoimmu-
nity.
77 4In each of these situations the possibility of NSAbs
should be considered in the future.
OTHER POSSIBLE NSAS
There are many reports of patients in whom an NSAb mediated
mechanism may be present even though they do not present as
one of the conditions described above. For example, there are
patients reported with epilepsy
75e77 or psychosis
34 35 78 with
GAD, VGKC complex or other NSAbs; others with GAD-Ab
associated nystagmus
79 or palatal tremor.
80e82 Moreover, there
are CNS disorders for which a role for autoantibodies has been
hypothesised but is still controversial. These include post-
streptococcal neurological and psychiatric syndromes, Syden-
ham’s chorea with antibodies targeting ‘basal ganglia antigens’
and also encephalopathies associated with systemic autoim-
munity (ie, antiphospholipid syndrome and neuropsychiatric
lupus) or organ speciﬁc conditions for which a vasculitic or
ischaemic mechanism can be excluded.
83 Hashimoto’s encepha-
lopathy, also called steroid responsive encephalopathy associated
with autoimmune thyroiditis, is an example of the latter group
and is only deﬁned by the presence of serum thyroperoxidase or
thyroglobulin antibodies, often without evidence of thyroid
dysfunction.
84 Given the high frequency of thyroid antibodies in
the normal population, it is likely that in some cases they are
incidental and that NSAbs are the real pathogenic agent; indeed,
thyroid antibodies were found coexisting with NMDAR or
VGKC-complex-Abs in a recent study of LE.
85 Finally, there are
many forms of childhood encephalitis and epilepsy which are
often treated with steroids but are not yet recognised as anti-
body mediated, although cases with VGKC complex, GAD or
NMDAR-Abs are beginning to be reported.
86 87 Below we
consider how one might go about recognising these conditions
and deﬁning NSAS for future diagnosis and management.
ANTIBODY SCREENING
Indirect immunohistochemisty or immunoﬂuorescence on ﬁxed
and/or frozen rat brain tissue is commonly used as a preliminary
screen to identify recognisable staining patterns that represent
intracellular or surface (eg, neuropil) antibodies, although
sensitivity, particularly for the latter, depends on laboratory
expertise. The target of the antibodies may be strongly suspected
from these results, but should be conﬁrmed by more speciﬁc
techniques. Commercial assays for immunoblotting with
recombinant proteins for the most common/well characterised
onconeural antibodies (Hu, Ma2, CV2/CRMP5, Ri, amphi-
physin) are widely available. GAD-Abs and VGKC complex
antibodies are often detected by radioimmunoassay but a GAD-
Ab ELISA and a GAD-Ab immunoblot test are also available.
The gold standard for NSAb detection (and for other anti-
bodies against cell surface antigensdeg, AQP4) is an assay based
on mammalian cells (generally human embryonic kidney cells)
transiently transfected with the antigen of interest and incu-
bated with the patient’s serum, diluted 1:10 or greater (or CSF,
usually diluted from 1:1e1:10). Positive samples are visually
identiﬁed at the (unpermeabilised) cell surface or throughout
the (permeabilised) cell using an antihuman IgG tagged with
a ﬂuorescent dye. This technique, commonly named a cell
based or cell binding assay, is sensitive and speciﬁc, as only one
antigenic target is overexpressed in these cells.
Given the plethora of antibodies that have been reported so
far, the clinician faced with the dilemma of which antibody to
test ﬁrst, especially if indirect immunohistochemisty or immu-
noﬂuorescence gave inconsistent results, should bear in mind
that most NSAb related CNS disorders are covered by NMDAR-
Abs and VGKC-complex Abs. If the sample proves negative for
both, it may be worth referring to a laboratory with research
experience in this area and requesting other antibodies.
However, multiple antibody testing (for NMDAR, LGI1,
CASPR2, AMPAR, GABABR and GlyR) may be the way forward
as there are now beginning to be commercial assays consisting of
mosaics of cells displaying different NSAbs (similar to the single
antibody test reported by Wandinger and colleagues
88).
If no antibodies are positive with these speciﬁc tests, immu-
nostaining of live hippocampal or other neurons may detect
other NSAbs in patients. This approach, not yet available
commercially, would allow detection of potentially pathogenic
NSAbs, justify immunotherapies and could lead to identiﬁcation
of new antigens in the future.
IMMUNOTHERAPY
There is no consensus or evidence base to indicate which type of
immunotherapies should be tried in these patients but in well
deﬁned syndromes it is thought important to start early,
without waiting for the results of the antibody determinations,
and while screening of the tumour is conducted. First-line
treatments are intravenous followed by oral high dose cortico-
steroids, intravenous immunoglobulins or plasma exchange, and
frequently a combination of these (plasma exchange preceding
intravenous immunoglobulins). Most patients with encephalitis
associated with NSAbs respond within weeks of ﬁrst-line
treatments but responses can be slow in patients with NMDAR-
Ab encephalitis. For non-responders, if the tumour screen is
negative, a second-line immunotherapy, with rituximab, cyclo-
phosphamide, or both, has been suggested.
10 There are no data
on the value of chronic long term immunotherapy to prevent
relapses in those syndromes that do so (mainly NMDAR-Ab
encephalitis) although patients who are not treated with
immunotherapy at the ﬁrst event seem to have a higher risk for
relapses.
89 Based on the authors’ experience, weaning should be
very careful. Serial estimations of antibody levels, in serum and
CSF if available, can be helpful.
APPROACH TO THE RECOGNITION OF NSAS
Well deﬁned syndromes
If the clinical features are typical of a well deﬁned syndrome,
such as LE or OMS, after exclusion of other potential causes
(infective, trauma, toxic, metabolic, tumours or histories of
previous CNS disease), the priority is to rule out a paraneoplastic
syndrome, as previously established.
2 A search for a tumour
should be undertaken and testing of serum, and CSF if possible,
performed for onconeural antibodies, for those NSAbs that are
currently available (NMDAR, VGKC complex proteins) and also
for GAD-Abs. If a tumour is found or if onconeural antibodies
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neurological syndrome,
2 and tumour therapy and immuno-
therapy can be performed. Irrespective of the presence of
a tumour, a positive NSAb would justify the diagnosis of NSAS
and more intensive immunotherapy; a screen for speciﬁc
tumours should be intensiﬁed (eg, teratoma for NMDAR-Abs or
thymoma for VGKC-Abs).
Suspected NSAS
In case of other neurological syndromes, the following
three criteria can be used to suggest a possible immune mediated
cause associated with an NSAb. Supportive features are not
mandatory but their presence would strengthen the diagnostic
suspicion and help the subsequent diagnostic classiﬁcation.
Criteria
< Acute or subacute (<12 weeks) onset of symptoms
< Evidence of CNS inﬂammation (at least one of):
– CSF (lymphocytic pleocytosis, CSF speciﬁc oligoclonal
bands or elevated IgG index);
– MRI (eg, mediotemporal lobes FLAIR/T2 hyperintensities
in case of a LE-like syndromedotherwise unexplained (eg,
post-seizure); or enhancement of cerebellar sulci) or
functional imaging (hypermetabolism on ﬂuorodeoxyglu-
cose-positron emission tomography or hyperperfusion on
single photon emission computed tomography in the
acuteesubacute phase);
– inﬂammatory neuropathology (lymphocytic inﬁltrates or
other signs of immune activation) on biopsy.
< Exclusion of other causes (infective, trauma, toxic, metabolic,
tumours, demyelinating or histories of previous CNS disease).
Supportive features
< History of other antibody mediated disorders (eg. MG) or
organ speciﬁc autoimmunity.
< Preceding infectious, febrile illness or viral disease-like
prodromes; this follows the recognition that (1) many cases
of autoimmune encephalitis (eg, NMDAR) are preceded
by prodromes and that (2) a CNS (as well as a peripheral
nervous system) disorder with an acute or subacute onset
following a viral disease can be generated by a parainfectious
autoimmune mechanism.
As all of these conditions can associate with tumours, screening
for onconeural antibodies should be performed.
2 If a tumour is
found or onconeural antibodies are positive, the syndrome will
be a paraneoplastic neurological syndrome, deﬁnite or possible
according to the Graus criteria.
2 Meanwhile, a search for NSAbs
and GAD-Abs should not be delayed, and while waiting for the
results, a trial of immunotherapy can be started. Even in patients
who are negative for the known NSAbs, a trial with steroids and
Figure 1 Flowchart indicating our suggestions for approaches to the recognition and diagnostic criteria for the neuronal surface antibody syndromes
(NSAS). The ﬁeld is developing and the scheme is intended to help identify further NSAS. *For details, see Graus et al.
2 **History of other antibody
mediated disorders or organ speciﬁc autoimmunity, or previous infectious/febrile illness. GAD, glutamic acid decarboxylase; IVIG, intravenous
immunoglobulins; NSAbs, neuronal surface antibodies; OMS, opsoclonusemyoclonus syndrome; PE, plasma exchange; SPS, stiff person syndrome.
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considered if there are no contraindications, particularly if
infectious diseases have been ruled out.
Ultimately a diagnostic classiﬁcation as deﬁnite, probable or
possible NSAS will depend on the clinical presentation, antibody
testing and response to immunotherapies (ﬁgure 1). Positive
antibodies may sometimes be misleading, as very low titres (eg,
<1:50) can be found in patients with apparently unrelated
conditions (unpublished results), but at present there are no
standards for assessing the NSAbs and more data are needed to
explore the relationships between titres and clinical features. To
deﬁne a syndrome as immunotherapy responsive, a sustained
improvement in the modiﬁed Rankin score of at least 1 point
would be appropriate.
5
The following diagnostic deﬁnitions are not only for ‘classi-
ﬁcation’ but are aimed at helping to justify systematic antibody
testing, more intense immunotherapies and the search for novel
NSABs.
Classiﬁcation
< A diagnosis of deﬁnite NSAS can be made if known NSAbs are
present in the serum or CSF AND there is a response to
immunotherapies.
< A diagnosis of probable autoimmune NSAS can be made if:
– known NSAbs are present
– OR there are other neuronal antibody markers of an
immune process (GAD-Ab, unknown neuronal surface/
neuropil antibodies) or at least one of the above mentioned
clinical supportive features AND there is a response to
immunotherapies.
< If clinical and paraclinical criteria suggest a possible NSAS,
but no known NSAbs are found, a diagnosis of possible
autoimmune NSAS can still be made if:
– other neuronal antibody markers of an immune process
(GAD-Ab, unknown neuronal surface/neuropil antibodies)
or at least one of the above mentioned clinical supportive
features are present
– OR there is a response to immunotherapies.
A diagnosis of probable or possible NSAS will prompt search for
novel unknown antibodies or a second line immunotherapy
(with or without tumour screening). An alternative diagnosis
will be warranted in any other case (see ﬁgure 1).
CONCLUSIONS
This new ﬁeld of immune mediated CNS diseases is exciting but
also challenging. There is a need for more intense research into
those conditions that are shown to be immunotherapy respon-
sive and thereby can be deﬁned as possible NSAS. The presence
of these and other NSAbs in patients with more common
conditions, such as epilepsy, psychosis and dementia, needs to be
systematically examined. Ideally, antibody testing should be
performed in local laboratories using internationally validated
procedures so that the diagnosis can be made and treatments
started as soon as possible in the hope of restoring health,
limiting hospitalisation and optimising outcomes. Systematic
studies of the treatments are needed in order to establish best
practice.
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